1. Healthcare

  2. •

    Biotechnology
SteadyMed Ltd.

SteadyMed Ltd.

STDY
SteadyMed Ltd.US flagNASDAQ
4.73
USD
- -
- -
SteadyMed Ltd.
STDY
(NASDAQ)

Recent

price

4.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
TTM
FRC
- -
- -
0.08
0.07
0.04
0.02
Revenue per Share
-1.42
-3.28
-2.45
-1.59
-0.95
-0.64
Basic EPS, GAAP
-1.16
-2.12
-2.21
-1.74
-0.98
-0.85
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.85
-5.66
-5.97
-5.48
-4.6
-4.99
Book Value per Share
-2.59
0.8
2.69
0.88
0.98
0.16
Tangible Book Value per Share
7
7
11
16
24
27
Basic Weighted Avg Shares
- -
- -
1
1
1
- -
Sales/Revenue/Turnover
- -
- -
-2,840.62
-2,572.58
-1,918.78
-5,422.33
Operating Margin (%)
- -
- -
- -
1
1
1
Depreciation Expense
-8
-19
-25
-26
-23
-17
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-2,873.53
-2,429.01
-2,178.87
-3,935.81
Profit Margin (%)
2
3
27
17
30
17
Working Capital
1
- -
- -
- -
- -
- -
LT Debt
-18
5
29
14
24
4
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
88
84
120

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
33
27
21
Cash, Cash Equivalents & STI
32
27
21
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
4
Payables & Accruals
2
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
66.38%
Free Cash Flow
- -
- -
-15.17%
Net Income, GAAP
- -
- -
-10.3%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
1
2017
- -
- -
- -
- -
1
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.46
-0.53
-0.57
- -
-1.59
2017
-0.92
-0.33
0.35
- -
-0.95
2018
-0.39
-0.38
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
GeNeuro S.A. (GNRRF)
Outlook Therapeutics, Inc. - Se (OTLKW)
Silence Therapeutics plc (SLNCF)
Telescope Innovations Corp. (TELI.CN)
Lipocine Inc. (LPCN)
Radiopharm Theranostics Limited (RAD.AX)
Business
SteadyMed Ltd. (STDY) operates as a specialty pharmaceutical company focused on developing and commercializing drug product candidates for orphan and high-value diseases with unmet parenteral delivery needs; its proprietary PatchPump technology enables discreet, water-resistant, disposable subcutaneous drug administration for high-volume liquids, including small molecules and biologics. Core products include the lead candidate Trevyent, a treprostinil subcutaneous infusion for pulmonary arterial hypertension via PatchPump; additional pipeline candidates target post-surgical and acute pain management in home settings. Founded in 2005 and headquartered in San Ramon, California, with operations in the United States, Israel, and Europe, the company serves patients requiring advanced parenteral therapies. In 2018, United Therapeutics Corporation completed its acquisition of SteadyMed, delisting STDY shares from NASDAQ and integrating its assets as a subsidiary.